Skip to main content
RUA LIFE SCIENCES PLC logo

RUA LIFE SCIENCES PLC — Investor Relations & Filings

Ticker · RUA ISIN · GB0033360586 LEI · 213800BMVB22PVOJ9Z28 IL Manufacturing
Open in API
Filings indexed 200 across all filing types
Latest filing 2020-12-11 Capital/Financing Update
Country GB United Kingdom
Listing IL RUA

About RUA LIFE SCIENCES PLC

https://rualifesciences.com/

RUA Life Sciences is a medical device group focused on the application of its proprietary long-term implantable polymer, Elast-Eon™, a biostable polyurethane. The company operates through four integrated businesses to develop, manufacture, and license medical device solutions. RUA Biomaterials is responsible for licensing the Elast-Eon™ technology. RUA Medical provides end-to-end contract development and manufacturing services, specializing in implantable fabrics. RUA Vascular develops large-bore, polymer-sealed vascular grafts and soft tissue patches. RUA Structural Heart is engaged in the development of next-generation tri-leaflet polymeric heart valves. The group's collective mission is to improve patient outcomes by enabling and enhancing medical devices through its advanced polymer technology.

Recent filings

Filing Released Lang Actions
Fundraising and Appointment of Joint Broker
Capital/Financing Update Classification · 1% confidence The document is an official announcement released via RNS (RNS Number : 4367I) on December 11, 2020. The content details a 'Conditional Placing and Subscription to raise £6.0m' and an 'Open Offer to Qualifying Shareholders to raise up to a further £1.0m'. This clearly describes a fundraising activity involving the issuance of new shares and capital structure changes. This aligns perfectly with the definition of 'Capital/Financing Update' (CAP). Although it mentions a General Meeting to approve the resolutions, the primary purpose and focus of the announcement is the capital raise itself, not the voting results (DVA) or the proxy materials (PSI). It is not a full report (10-K, IR) but a specific corporate action announcement.
2020-12-11 English
Half-year Report
Interim / Quarterly Report Classification · 1% confidence The document is titled 'Unaudited Interim Results' for RUA Life Sciences plc for the six months ended 30 September 2020. It contains comprehensive financial statements, including an income statement, statement of financial position, and cash flow statement. It is not a mere announcement of a report, as it provides the full interim financial data and management commentary. Therefore, it is classified as an Interim/Quarterly Report. H1 2020
2020-12-11 English
Directorate Change
Board/Management Information Classification · 1% confidence The document is identified by the RNS Number header and the closing statement referencing RNS, the news service of the London Stock Exchange. The core content announces that 'Gordon Wright has resigned as a non-executive Director of the Company'. This directly corresponds to the definition of Board/Management Information (MANG), which covers announcements of changes in the company's board of directors or senior management.
2020-12-11 English
ENDRA Announces New Clinical Study Partnership
Legal Proceedings Report Classification · 1% confidence The document is a press release disseminated via RNS (RNS Number: 5821H) and DGAP-News. It announces a new clinical study partnership and provides details about the study, the technology involved (TAEUS), and the involved parties. It is not a full financial report (10-K or IR), an earnings release (ER), or a proxy statement (DEF 14A). Since it is a general corporate announcement distributed through regulatory/news channels (RNS/DGAP) that doesn't fit the specific categories like M&A (TAR), Capital Change (CAP), or Director Dealing (DIRS), the most appropriate classification is the general regulatory announcement/news category, RNS, or potentially an announcement related to research/development which might fall under Regulatory Filings if RNS is too broad, but RNS is explicitly mentioned as a distribution channel and a fallback. Given the content is a specific corporate news announcement distributed via RNS, RNS is the best fit among the provided options for a general news release that isn't a core financial filing or specific event announcement.
2020-12-04 English
Successful completion of Heart Valve Testing
Earnings Release Classification · 1% confidence The document is identified by the header 'RNS Number : 0823G' and contains a date (23 November 2020) and company information, typical of a regulatory news service announcement. The content describes a specific operational update ('Successful completion of Heart Valve Testing') and references a previous 'Trading Update'. This format—a brief announcement of a specific, non-financial event or operational milestone, disseminated via RNS—does not fit the comprehensive nature of a 10-K, IR, or ER. It is not a management change (MANG), director dealing (DIRS), or dividend notice (DIV). Since it is a specific operational announcement distributed through the regulatory news service (RNS), and it is not a general fallback, the most appropriate classification is the general Regulatory Filings category (RNS), as it is a standard regulatory news release detailing a corporate event. FY 2020
2020-11-23 English
Trading Update
Earnings Release Classification · 1% confidence The document is titled 'Trading Update' and provides a performance summary for the six months ended 30 September 2020, detailing operational updates for various business segments (RUA Biomaterials, RUA Medical Devices, RUA Vascular, RUA Structural Heart) and concluding with a cash position update. It explicitly states that the company 'will provide a further update at the time of release of its unaudited interim results for the six months ended 30 September 2020, which are expected to be released in mid-December 2020.' This structure—a brief update on interim performance without full financial statements—is characteristic of an Earnings Release (ER) or a precursor to a full Interim Report (IR). Since it provides key highlights and operational status for a defined interim period (six months), it fits the definition of an Earnings Release (ER) better than the comprehensive Interim Report (IR) which is expected later. The presence of the RNS Number and the LSE distribution boilerplate confirms it is a regulatory announcement. H1 2021
2020-10-23 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.